NEW YORK, Aug. 27, 2018 (GLOBE NEWSWIRE) — Tyme Technologies, Inc. (NASDAQ:TYME), a clinical-stage oncology company developing metabolically-based cancer therapeutics, today announced that it will be featured as a presenting company at the Rodman & Renshaw 20th Annual Global Investment Conference. The conference is being held on September 4-6, 2018 at the St. Regis New York Hotel in New York.
Ben Taylor, President and Chief Financial Officer of Tyme, will provide an overview of the Company’s business during the presentation, and other members of management will be available to participate in one-on-one meetings with investors who are registered to attend the conference.
Event: Rodman & Renshaw 20th Annual Global Investment Conference
Date: Wednesday, September 5, 2018
Time: 4:15-4:40 PM EST
Location: Fontainebleau Room (2nd floor)
The presentation will be webcast live. To access the webcast, please visit the Company’s website, https://ir.tymeinc.com/events-and-presentations, or (http://wsw.com/webcast/rrshq28/tyme/). The webcast replay will remain available for 90 days following the live presentation.
If you are an institutional investor, and would like to attend the Company’s presentation, please click on the following link (www.rodmanevents.com) to register for the conference. Once your registration is confirmed, you will be prompted to log into the conference website to request a one-on-one meeting with the Company.
About Tyme Technologies
Tyme Technologies, Inc., is a clinical-stage biotechnology company developing cancer therapeutics that are intended to be broadly effective across tumor types and have low toxicity profiles. Unlike targeted therapies that attempt to regulate specific mutations within cancer, the Company’s therapeutic approach is designed to take advantage of a cancer cell’s innate metabolic weaknesses to compromise its defenses, leading to cell death through oxidative stress and exposure to the body’s natural immune system.
For more information, visit www.tymeinc.com.
LifeSci Advisors LLC
Ashley R. Robinson